Cargando…

Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model

Background. Bacillus Calmette-Guerin (BCG) vaccine is the most widely administered vaccine in the world, yet its mechanism of action remains unclear. We hypothesize that certain immune pathways are associated with reduced mycobacterial growth following BCG challenge in human volunteers. Methods. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumiya, Magali, Satti, Iman, Chomka, Agnieszka, Harris, Stephanie A., Stockdale, Lisa, Meyer, Joel, Fletcher, Helen A., McShane, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392868/ https://www.ncbi.nlm.nih.gov/pubmed/25381367 http://dx.doi.org/10.1093/infdis/jiu615

Ejemplares similares

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
por: Tanner, Rachel, et al.
Publicado: (2020)

Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity
por: Minhinnick, Alice, et al.
Publicado: (2016)

A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-Guérin
por: Minassian, Angela M., et al.
Publicado: (2012)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
por: Harris, Stephanie A., et al.
Publicado: (2014)

T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
por: Matsumiya, Magali, et al.
Publicado: (2014)

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
por: O’Shea, Matthew K., et al.
Publicado: (2018)

Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction
por: Chen, Tingting, et al.
Publicado: (2016)

Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines
por: Harris, Stephanie A., et al.
Publicado: (2018)

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
por: Satti, Iman, et al.
Publicado: (2022)

BCG Vaccination Induces Different Cytokine Profiles Following Infant BCG Vaccination in the UK and Malawi
por: Lalor, Maeve K., et al.
Publicado: (2011)

The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays
por: Tanner, Rachel, et al.
Publicado: (2017)

Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays
por: Tanner, Rachel, et al.
Publicado: (2019)

Editorial Commentary: Understanding BCG Is the Key to Improving It
por: McShane, Helen
Publicado: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
por: Satti, Iman, et al.
Publicado: (2014)

Historical BCG vaccination combined with drug treatment enhances inhibition of mycobacterial growth ex vivo in human peripheral blood cells
por: Prabowo, Satria A., et al.
Publicado: (2019)

Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A
por: Matsumiya, Magali, et al.
Publicado: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial
por: Rowland, Rosalind, et al.
Publicado: (2013)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1
por: Fletcher, Helen A., et al.
Publicado: (2008)

Regulation of mycobacterial infection by macrophage Gch1 and tetrahydrobiopterin
por: McNeill, Eileen, et al.
Publicado: (2018)

Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy
por: Naranbhai, Vivek, et al.
Publicado: (2014)

Cytomegalovirus infection is a risk factor for tuberculosis disease in infants
por: Müller, Julius, et al.
Publicado: (2019)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)

A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis
por: Zelmer, Andrea, et al.
Publicado: (2016)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Recombinant BCG ΔureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses
por: Desel, Christiane, et al.
Publicado: (2011)

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
por: Tanner, Rachel, et al.
Publicado: (2021)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
por: Sheehan, Sharon, et al.
Publicado: (2015)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth
por: Fletcher, Helen A, et al.
Publicado: (2009)

The Humoral Immune Response to BCG Vaccination
por: Tanner, Rachel, et al.
Publicado: (2019)

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study
por: Wilkie, Morven, et al.
Publicado: (2022)

Human Hookworm Infection Enhances Mycobacterial Growth Inhibition and Associates With Reduced Risk of Tuberculosis Infection
por: O'Shea, Matthew K., et al.
Publicado: (2018)

Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines
por: Smith, Steven G., et al.
Publicado: (2015)

Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination
por: Bitencourt, Julia, et al.
Publicado: (2022)

Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy
por: Minassian, Angela M., et al.
Publicado: (2011)

MYCOBACTERIAL ABSCESSES AFTER BCG VACCINATION
por: Brennan, R, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8kbub3lgib7qiulp0icbtonmn1